SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC US FDA Inspections 8-K Filing 2024 - Clinical Trial Update Shuttle Pharmaceuticals announced the first patient enrollment and dosing in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, involving 40 patients to determine the optimal dose.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC